Viz.ai has entered into a multi-year collaboration with Sanofi and Regeneron to implement an AI-driven workflow solution for chronic obstructive pulmonary disease (COPD).
The partnership aims to enhance the detection and management of high-risk COPD patients through the Viz COPD module, which will utilise electronic health record (EHR) data and AI.
Sanofi and Regeneron will support Viz.ai in deploying this care acceleration solution, which employs natural language processing to screen and triage patients according to clinical guidelines.
Sanofi Specialty Care medical head Paul Rowe said: “At Sanofi, we’re excited to collaborate with Viz.ai to further address unmet needs in COPD care by leveraging AI.
“With this collaboration, we will study the impact of the Viz COPD module, a streamlined AI-enabled EHR workflow to improve access to care and ultimately patient outcomes in COPD, a disease that remains under-prioritised, underfunded and undertreated in comparison to other noncommunicable diseases.”
The module aims to identify high-risk individuals, ensuring they receive the necessary follow-up and care.
The Viz COPD module is designed to leverage Viz.ai’s existing network, which includes over 1,700 hospitals and health systems and more than 60,000 healthcare providers. This initiative seeks to improve diagnosis and care across various disease areas, with a particular focus on respiratory conditions.
By integrating AI technology with EHR data, the collaboration between Viz.ai, Sanofi, and Regeneron aims to optimise patient outcomes, especially for those who require enhanced follow-up and care.
Viz.ai’s partnership with Sanofi and Regeneron underscores a commitment to advancing healthcare through innovative technology. The deployment of the Viz COPD module represents a significant step in using AI to streamline patient care and improve health outcomes.
Viz.ai CEO and co-founder Chris Mansi said: “This collaboration with Sanofi and Regeneron is a major step forward in our mission to expand AI-driven care coordination across disease areas with critical unmet needs, such as COPD.
“Our approach aims to empower healthcare providers to deliver data-driven, guideline-directed care that meaningfully impacts patient outcomes. We look forward to collaborating with Sanofi and Regeneron to harness AI to accelerate advancements in disease management and improve patient access to care.”
